DRUG INTERACTION
Severity :
Monitor Closely
may enhance the serum concentration of CYP3A4 inhibitors
No drug interaction found for isoniazid and .
Contraindicated
ethinyl estradiol
may decrease the levels of serum concentration of hormonal contraceptives
etonogestrel
may decrease the levels of serum concentration of hormonal contraceptives
ethinylestradiol
may decrease the levels of serum concentration of hormonal contraceptives
mibefradil
may enhance the QTc-prolonging effect of QT-prolonging agents
ibandronate
may enhance the QTc-prolonging effect of QT-prolonging agents
trazodone
may enhance the QTc-prolonging effect of QT-prolonging agents
isradipine
may enhance the QTc-prolonging effect of QT-prolonging agents
treprostinil
may enhance the QTc-prolonging effect of QT-prolonging agents
nilotinib
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
clofazimine
may increase the serum concentration of CYP3A4 substrates
deflazacort
may enhance the serum concentrations of active metabolites
rifampin
may diminish the serum concentration
abiraterone
may diminish the serum concentration of CYP3A4 inducers
dasatinib
may diminish the serum concentration of CYP3A4 inducers
dexamethasone
may diminish the serum concentration of CYP3A4 inducers
nifedipine
may decrease the serum concentration when combined with CYP3A4 Inducers (Strong)
abemaciclib
may increase the serum concentration of abemaciclib
adagrasib
may increase the level of serum concentration of adagrasib
sparsentan
may increase or decrease the activity of this enzyme when combined with sparsentan
alfentanil
may diminish the serum concentration when combined with alfentanil
apixaban
may diminish the serum concentration when combined with apixaban
aripiprazole
may diminish the serum concentration when combined with aripiprazole
atogepant
may diminish the serum concentration when combined with atogepant
belumosudil
may diminish the serum concentration when combined with belumosudil
brexpiprazole
may diminish the serum concentration when combined with brexpiprazole
ubrogepant
may diminish the serum concentration when combined with ubrogepant
fenfluramine
may diminish the serum concentration when combined with fenfluramine
brivaracetam
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
cabozantinib
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel
clopidogrel: they may enhance serum concentrations of CYP2C19 Inducers
cyclosporine
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
diltiazem
diltiazem: they may diminish the serum concentration of CYP3A4 Inducers
enzalutamide
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
eravacycline
CYP3A4 inducers: they may diminish the serum concentration of eravacycline
erlotinib
erlotinib: they may diminish the serum concentration of CYP3A4 inducers
etoposide
etoposide: they may diminish the serum concentration of CYP3A4 inducers
exemestane
exemestane: they may diminish the serum concentration of CYP3A4 Inducers
felodipine
felodipine: they may diminish the serum concentration of CYP3A4 Inducers
ganaxolone
CYP3A4 inducers: they may diminish the serum concentration of ganaxolone
sotorasib
may diminish the serum concentration of zanubrutnib
Serious Use Alternative
lorlatinib
the effect of isoniazid is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
ruxolitinib
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fexinidazole
it increases the concentration of CYP3A4 substrates in the serum
fusidic acid
it increases the concentration of CYP3A4 substrates in serum
doravirine
they decrease the concentration of doravirine in the serum
rilpivirine
they decrease the concentration of rilpivirine
macimorelin
may decrease the serum concentration of macimorelin
lenacapavir
may decrease the serum concentration of lenacapavir
buprenorphine
they decrease the concentration of buprenorphine in the serum
abemaciclib
may reduce the level of serum concentration of abemaciclib
adagrasib
may diminish the serum concentration of CYP3A4 inducers
alpelisib
may diminish the serum concentration of CYP3A4 inducers
apremilast
may diminish the serum concentration of CYP3A4 inducers
asunaprevir
may diminish the serum concentration of CYP3A4 inducers
avanafil
may diminish the serum concentration of CYP3A4 inducers
bedaquiline
may diminish serum concentrations of CYP3A4 inducers
bortezomib
may diminish the serum concentration of CYP3A4 inducers
deflazacort
may diminish serum concentrations of CYP3A4 inducers
glasdegib
they decrease the concentration of glasdegib in the serum
infigratinib
they decrease the concentration of active metabolites of infigratinib in the serum
infigratinib
they decrease the concentration of active metabolites of infigratinib in the serum
pimozide
CYP3A4 inhibitors increase the concentration of pimozide in the serum
buspirone
it increases the concentration of CYP3A4 substrates in the serum
tafamidis
may enhance the serum concentration of tafamidis
tolvaptan
may diminish the serum concentration when combined with tolvaptan
abrocitinib
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
capmatinib
CYP3A4 Inducers: they may diminish the serum concentration of capmatinib
ceritinib
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
avacopan
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
lurbinectedin
they decrease the concentration of lurbinectedin in the serum
Monitor Closely
almasilate
antacids reduce the systemic absorption of isoniazid
magaldrate
antacids reduce the systemic absorption of isoniazid
estropipate
may reduce the level of serum concentration of estrogen drugs
estropipate
may increase the levels of serum concentration of estrogen derivatives
anastrozole
may increase the levels of serum concentration of estrogen derivatives
estetrol
may increase the levels of serum concentration of estrogen derivatives
ethinyl estradiol
may increase the levels of serum concentration of hormonal contraceptives
etonogestrel
may increase the levels of serum concentration of hormonal contraceptives
ethinylestradiol
may increase the levels of serum concentration of hormonal contraceptives
acetaminophen
may have an increased hepatotoxic effect when combined with acetaminophen
valrubicin
may increase the levels of serum concentration
doxorubicin
may increase the levels of serum concentration
epirubicin
may increase the levels of serum concentration
mitomycin
may increase the levels of serum concentration
tivozanib
may increase the levels of serum concentration
abemaciclib
may increase the levels of serum concentration
bosutinib
may increase the levels of serum concentration
topotecan
may decrease the levels of serum concentrations
epirubicin
may decrease the levels of serum concentrations
etoposide
may decrease the levels of serum concentrations
irinotecan
may decrease the levels of serum concentrations
topotecan
may decrease the levels of serum concentrations
etoposide
may decrease the levels of serum concentrations
irinotecan
may decrease the levels of serum concentrations
teniposide
may decrease the levels of serum concentrations
dacomitinib
may decrease the levels of serum concentration
pacritinib
may decrease the levels of serum concentration
asciminib
may decrease the levels of serum concentration
pemigatinib
may decrease the levels of serum concentration
etoposide
when both drugs are combined, there may be a reduced metabolism of etoposide
vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
brentuximab
has a synergistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
abemaciclib
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
finasteride
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
lacosamide
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
clorazepate
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
triazolam
may enhance the serum concentration of CYP3A4 inhibitors
ziconotide
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
clozapine
may decrease the levels of serum concentration of clozapine
ospemifene
may increase the serum concentration of CYP3A4 substrates
erdafitinib
may decrease the serum concentration of erdafitinib.
macitentan
may decrease the serum concentration of macitentan
macitentan
may enhance the serum concentration of macitentan
pretomanid
may decrease the level of serum concentration of pretomanid
eliglustat
CYP3A4 Inducers may decrease the serum concentration of eliglustat
encorafenib
may decrease the serum concentration of encorafenib
estropipate
may decrease the serum concentration of estrogen derivatives
estetrol
may decrease the serum concentration of estrogen derivatives
prednisolone
may diminish the serum concentration of corticosteroids
may enhance the serum concentration of CYP3A4 inhibitors
amlodipine
may diminish the serum concentration of CYP3A4 inducers
atorvastatin
may diminish the serum concentration of CYP3A4 inducers
benperidol
may diminish the serum concentration of CYP3A4 inducers
bisoprolol
may diminish the serum concentration of CYP3A4 inducers
cabazitaxel
may diminish the serum concentration of CYP3A4 inducers
calcifediol
may diminish the serum concentration of CYP3A4 inducers
carbamazepine
may diminish the serum concentration of CYP3A4 inducers
chlorpropamide
may diminish the serum concentration of CYP3A4 inducers
clonazepam
may diminish the serum concentration of CYP3A4 inducers
escitalopram
may diminish the serum concentration of CYP3A4 inducers
doxercalciferol
may enhance serum concentrations when combined with doxercalciferol
itraconazole
may increase the level of serum concentration of itraconazole
itraconazole
may decrease the level of serum concentrations of itraconazole
selpercatinib
may diminish the serum concentration when combined with selpercatinib
nimodipine
may diminish the serum concentration when combined with nimodipine
upadacitinib
may diminish the serum concentration when combined with upadacitinib
tivozanib
may reduce the levels of serum concentration of tivozanib
nintedanib
may diminish the serum concentration when combined with nintedanib
ziprasidone
may diminish the serum concentration when combined with ziprasidone
lovastatin
may enhance the serum concentration when combined
eszopiclone
eszopiclone: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
hydrocodone
hydrocodone: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
meperidine
meperidine: they may diminish the serum concentration of CYP3A4 Inducers
methadone
methadone: they may diminish the serum concentration of CYP3A4 Inducers
alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
amiodarone
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
roflumilast
may increase the levels of serum concentration
ribociclib
may increase the levels of serum concentration
triptorelin
may increase the levels of serum concentration
elagolix
may increase the levels of serum concentration
triptorelin
may decrease the levels of serum concentration
elagolix
may decrease the levels of serum concentration
ergonovine
may decrease the levels of serum concentration
ergometrine
may decrease the levels of serum concentration
Minor
ixazomib
isoniazid, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
remifentanil
CYP3A4 inducers decrease the concentration of opioids
codeine
CYP3A4 inducers decrease the concentration of opioids
morphine
CYP3A4 inducers decrease the concentration of opioids
Adult
Pediatric
Geriatric
Dosage Forms & Strengths
Tablets
50mg
100mg
300mg
Tuberculosis (TB)
Latent tuberculosis infection :
>30kg:300mg orally every day for nine months
3-month regimen
900mg orally weekly once for three months
Active tuberculosis disease
5mg/kg orally/intramuscularly every day.Do not exceed 300mg every day
Dosage Forms & Strengths
Tablets
50mg
100mg
300mg
Tuberculosis (TB)
Latent tuberculosis infection :
10-15mg/kg orally every day
3-month regimen
<2 years: Not recommended
>12 years: 900mg orally weekly once for three months
Active tuberculosis disease
10-15mg/kg orally every day. Do not exceed 300mg every day
Frequency defined:
>10%
Peripheral neuropathy
Nausea
Stomach pain
Loss of appetite
Vomiting
Weakness
1-10%
Slurred speech
Progressive liver damage
Dizziness
Lethargy
Hyperreflexia
<1%
Anemia
Thrombocytopenia
Agranulocytosis
Megaloblastic anemia
Systemic lupus erythematous
Pregnancy consideration: C
Lactation: The drug is excreted in the human breast milk and is safe for nursing women
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: isoniazid
Pronounced : [ eye-so-NYE-a-zid ]
Why do we use isoniazid ?
Isoniazid is an antibiotic used to treat and prevent tuberculosis (TB). It belongs to a class of antibiotics called antituberculosis agents. Isoniazid is used to treat TB infections in the lungs and other parts of the body. It is typically used in combination with other TB medications to ensure that the infection is fully treated and to prevent the development of drug-resistant TB